19 research outputs found
sj-pdf-1-jpc-10.1177_21501319241240355 – Supplemental material for Integrated Care Model by the Village Health Volunteers to Prevent and Slow down Progression of Chronic Kidney Disease in a Rural Community, Thailand
No full textSupplemental material, sj-pdf-1-jpc-10.1177_21501319241240355 for Integrated Care Model by the Village Health Volunteers to Prevent and Slow down Progression of Chronic Kidney Disease in a Rural Community, Thailand by Ampornpan Theeranut, Nonglak Methakanjanasak, Sunee Lertsinudom, Pattama Surit, Nichanun Panyaek, Saisamon Leeladapattarakul, Peangtikumporn Nilpetch, Pattapong Kessomboon, Chalongchai Chalermwat, Watcharapong Rintara, Wudipong Khongtong, Pawich Paktipat, Pannee Banchonhattakit, Darunee Chunlertrith, Amod Sharma, Ubon Cha’on and Sirirat Anutrakulchai in Journal of Primary Care & Community Health</p
Clinical outcomes and quality of life of asthma patients in Asthma Clinic, Tertiary Care Hospital in Thailand
No full textComparing pharmacist time use for asthma and COPD patients using various types of inhaler devices
No full textPharmacist's time spending to manage patients with asthma or COPD in an outpatient clinic in Thailand
No full textImpacts of pharmacist-led smoking cessation program on patients with chronic diseases in a Thai community hospital
No full textSmoking Cessation Services by Community Pharmacists: Real-World Practice in Thailand
No full textThis study aimed to report the effectiveness of community pharmacy smoking cessation services in 13 health regions in Thailand using a retrospective data-collecting method from the Foundation of Community Pharmacy database. The participants were smokers aged at least 18 years. The outcomes were the abstinence of smoking at least 30 consecutive days by self-report only and self-report with exhaled CO level <7 ppm (if available), the number of cigarettes smoked daily, exhaled carbon monoxide (exhaled CO), and % peak expiratory flow rate (%PEFR); smokers measured these outcomes before and after receiving the smoking cessation services. Of 58 community pharmacies, 532 smokers (93% male, mean age of 42.4 ± 14.9 years) received smoking cessation services from community pharmacists. Of 235 smokers with complete data, 153 (28.8%, 153/532) smokers reported smoking abstinence by self-report. The mean number of cigarettes smoked daily reduced from 15.3 ± 8.7 to 1.9 ± 3.8 cigarettes, p-value < 0.001. The exhaled CO levels of smokers significantly reduced from 11.7 ± 5.9 ppm to 7.2 ± 4.4 ppm, p-value < 0.001. The %PEFR also significantly increased from 84.2 ± 19.4 to 89.5 ± 19.5, p-value < 0.001. In conclusion, Thai community pharmacy smoking cessation services could aid smokers to quit smoking. This study is the outcome of the real-world community pharmacy smoking cessation service; policymakers should consider this service to be included in the national healthcare policy
Development of Chronic Kidney Disease Screening Integrative Care Model Led by Community Pharmacists
No full textBackground: The prevalence of chronic kidney disease (CKD) is rising, increasing demand for renal replacement therapy (RRT). Community pharmacies, as accessible healthcare hubs, can play a pivotal role in CKD prevention. This study aimed to develop care models for community pharmacies to optimize medication use, encourage behavior modification, and promote self-management among at-risk individuals. Methods: Conducted between June 2017 and July 2018, this study utilized an action research approach. Microalbuminuria was assessed using urine dipsticks, and pharmacists applied behavioral change and self-management support (SMS) strategies to slow CKD progression. Participants were categorized by albuminuria levels and enrolled in pharmacist-led care programs, with follow-up assessments at weeks 0 and 12. Results: Of 521 participants screened, 57% tested positive for albuminuria. For these individuals, serum creatinine testing and referrals to primary care were initiated. Self-management behavior assessment (S1) scores significantly improved (p = 0.024). Key factors associated with urine albumin levels included age 2 (OR = 0.42), eGFR ≥ 60 mL/min/1.73 m2 (OR = 3.34), lower systolic (OR = 0.55) and diastolic blood pressure (OR = 0.34), and fasting plasma glucose < 126 mg/dL (OR = 0.29). Conclusions: Community pharmacist-led albuminuria screening effectively supports CKD prevention and enhances self-awareness within communities
Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment
No full textIntravenous levetiracetam has been approved for use as an antiepileptic drug, as well as in cases of status epilepticus. There are few reports that detail the clinical data and outcomes associated with this antiepileptic drug, particularly in patients with renal impairment. This was a retrospective analytical study conducted at Khon Kaen University’s Srinagarind Hospital in Thailand. The study period was between January 1, 2010 and December 31, 2014. The inclusion criteria were that patents were over 15 years old, had renal impairment, and had received intravenous levetiracetam treatment. The main clinical outcomes were seizure control and mortality. Clinical outcomes were compared between those with and without status epilepticus. Mortality of patients with status epilepticus were compared in terms of seizure control and order of intravenous levetiracetam treatment. During the study period, there were 247 patients who met the study criteria. The average age of the patients was 58 years with nearly equal sex distribution. Of those, 90 patients (36.4%) had GRFs of less than 15 mL/min/1.73 m2 and 60 patients (24.3%) received intravenous LEVE due to status epilepticus. The seizure control rates in the status epilepticus and non-status epilepticus groups were 36.7% and 88.7%, respectively (P<0.001). The mortality rate did not differ significantly between the two groups (33.3% vs 27.8%; P=0.418). There was no significant overall difference in mortality rate between seizure-controlled and seizure-uncontrolled patients in the status epilepticus group. In the convulsive status epilepticus group, variations in terms of treatment order of intravenous levetiracetam and seizure control resulted in no significant difference in mortality rates (P=0.311). No major side effects were detected in any patients after the intravenous levetiracetam treatment. In conclusion, intravenous levetiracetam treatment was effective and safe in patients with renal impairment
Regulation of gonadotropin releasing hormone (GnRH) secretion : in-vitro studies in the male rat
No full textThe study described in this thesis was carried out between 1986—1990 while the author was a postgraduate candidate at The University of Sydney, and in receipt of a scholarship from the Australian International Development Assistance Bureau (AIDAB), Department of Foreign Affairs and Trade. The author would like to thank AIDAB for its financial support.
During this time, all experimental work and data analysis was carried out by the author, with excellent technical assistance from Mrs Jennifer Spaliviero and Miss Elsa Kidston. Experimental work involving animals was approved by the University of Sydney Animal Ethics Review Committee. Matters of design and interpretation were closely supervised by Associate Professor David J Handelsman, whose invaluable advice the author wishes to acknowledge.
This thesis has been arranged into six related chapters. The first section is a literature review. This section outlines the current state of knowledge concerning general~ aspects of gonadotropin—releasing hormone (GnRH) function, regulatory mechanisms of hypothalamic GnRH secretion, and the methodology suitable for investigation of the regulatory mechanisms of GnRH secretion from the medial basal hypothalamus (MBH) of adult male rats. Both systems are compared for features of methodological integrity, including stability of baseline GnRH release and technical limitations or artefacts. In the third part of this work, these in-vitro methods are applied to examine the effect of castration on GnRH secretion, the results of which are discussed in chapter three. The fourth section of this project concerns the effects of steroids, opioids and noradrenergic signals on GnRH secretion from MBH of adult male rats. In the fifth section of this project, the effect of experimental uremia as a model disease on GnRH secretion is addressed. The last chapter of this project is a summary and discussion. Since each chapter is discussed in detail, the final section is an overview of the content of previous chapters
Los Angeles County gang reduction project
No full textWithin Los Angeles County Latinos are disproportionately involved with gangs relative to the proportion of Latinos within the Los Angeles County population. Children of low-income Hispanic single-mothers and immigrant parents living in areas of concentrated poverty face multiple risk factors to gang involvement. By improving income levels these parents will be able to better provide for their children financially. A reduction in hours work as a result of improved earnings potential, along with improved parental capacity will in turn help to improve educational attainment and reduce delinquency among Latino youth. Project outcomes include an increase in skills and knowledge to improve earnings potential, improved access to and knowledge of available resources, community members that are empowered to create their own employment opportunities, and improved parental capacity to provide the structure and support needed for inter-generational upward mobility. While progress towards these outcomes has been made, project outcomes have not yet been achieved due to delays related to capacity limits. Continued partner and community engagement as well as improving capacity by expanding resources will be needed to successfully attain outcomes. (Author abstract)Thorsen, S. (2013). Los Angeles County gang reduction project. Retrieved from http://academicarchive.snhu.eduMaster of Science (M.S.)Community Economic DevelpopmentSchool of Busines
